ReviewCurrent diabetes reports2016
Diabetes and Schizophrenia.
Review in Current diabetes reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Repurposed antihypertensive drugs for negative symptoms in schizophrenia: A systematic review and meta-analysis.Psychiatry and clinical neurosciences · 2025Pooled it
- Relevance of diet in schizophrenia: a review focusing on prenatal nutritional deficiency, obesity, oxidative stress and inflammation.Frontiers in nutrition · 2024Pooled it
- Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.Frontiers in psychiatry · 2023Pooled it
- Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review.Current neuropharmacology · 2018Pooled it
- Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.BMC psychiatry · 2018Trial
- Polygenic Resilience Scores are Associated With Lower Penetrance of Schizophrenia Risk Genes, Protection Against Psychiatric and Medical Disorders, and Enhanced Mental Well-Being and Cognition.Schizophrenia bulletin · 2026Article
- The Risk of Very Late-Onset Schizophrenia Following Diabetes Type 2 Onset: A Nationwide Population-Based Study of Midlife and Old-Age.Schizophrenia bulletin · 2026Article
- Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Clinical Evidence.Journal of clinical medicine · 2026Review
- Vitamin D Adequacy Conditions the Prolactin-Suppressive Effect of Metformin in Men Receiving Prolactin-Elevating Medications.Nutrients · 2026Article
- Sexual Function and Depressive Symptoms in Metformin-Treated Women with Drug-Induced Hyperprolactinemia and Different Vitamin D Status: A Pilot Study.Pharmaceutics · 2026Article
- Trends in Diabetes Mellitus and Associated Mental Disorders-Related Mortality (1999-2023): A CDC WONDER Database Analysis.Brain and behavior · 2025Article
- Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).Molecular medicine reports · 2025Review
- Identification of Immune-Related Biomarkers of Schizophrenia in the Central Nervous System Using Bioinformatic Methods and Machine Learning Algorithms.Molecular neurobiology · 2025Article
- Managing health in dual diagnosis: narratives from individuals with schizophrenia and diabetes.Frontiers in psychiatry · 2025Article
- Association of SGLT2 inhibition with psychiatric disorders: A Mendelian randomization study.Open medicine (Warsaw, Poland) · 2025Article
- Exploring the Glycemic Control of Pay-for-Performance Program for Psychiatric Patients With Diabetes in Real World: A Retrospective Quasiexperimental Study.Journal of diabetes research · 2025Article
- Mind in Metabolism - A Comprehensive Literature Review on Diabetes and its Connections to Obsessive Compulsive Disorder, Schizophrenia, and Bipolar Disorder.Current diabetes reports · 2024Review
- One path, two solutions: Network-based analysis identifies targetable pathways for the treatment of comorbid type II diabetes and neuropsychiatric disorders.Computational and structural biotechnology journal · 2024Article
- Association of antipsychotic drugs on type 2 diabetes mellitus risk in patients with schizophrenia: a population-based cohort and in vitro glucose homeostasis-related gene expression study.BMC psychiatry · 2024Article
- The Interrelationship between Diabetes Mellitus and Emotional Well-Being: Current Concepts and Future Prospects.Healthcare (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with schizophrenia have 2- to 5-fold higher risk of type 2 diabetes than the general population. The traditional risk factors for type 2 diabetes, especially obesity, poor diet, and sedentary lifestyle, are common in people with schizophrenia already early in the course of illness. People with schizophrenia also often have low socioeconomic status and income, which affects their possibilities to make healthy lifestyle choices. Antipsychotic medications increase the risk of type 2 diabetes both directly by affecting insulin sensitivity and indirectly by causing weight gain. Lifestyle modification interventions for prevention of diabetes should be an integral part of treatment of patients with schizophrenia. In the treatment of type 2 diabetes in patients with schizophrenia, communication and collaboration between medical care and psychiatric treatment providers are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.